Strs Ohio Increases Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Strs Ohio raised its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 28.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,000 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Strs Ohio’s holdings in Omnicell were worth $188,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of OMCL. Covestor Ltd lifted its holdings in shares of Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after purchasing an additional 537 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Omnicell in the third quarter valued at about $62,000. Neo Ivy Capital Management purchased a new stake in shares of Omnicell in the third quarter valued at about $78,000. Fifth Third Bancorp lifted its holdings in shares of Omnicell by 143.2% in the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after purchasing an additional 1,313 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Omnicell by 110.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock valued at $153,000 after purchasing an additional 1,777 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL stock opened at $26.81 on Wednesday. Omnicell, Inc. has a one year low of $25.69 and a one year high of $77.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. The company has a 50 day moving average price of $27.61 and a 200 day moving average price of $31.93. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -59.58 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The firm had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. Sell-side analysts anticipate that Omnicell, Inc. will post 0.09 EPS for the current year.

Analyst Upgrades and Downgrades

OMCL has been the topic of several recent research reports. Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a report on Tuesday. Barclays started coverage on shares of Omnicell in a research report on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price objective for the company. Finally, Wells Fargo & Company cut their price objective on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.